Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: Analysis of over 500 patients

Highlights•5-year FFBF was 92% in patients with intermediate risk prostate cancer treated with 15 Gy HDR boost. •5-year MFS was 96% in patients with intermediate risk prostate cancer treated with 15 Gy HDR boost.

Saved in:
Bibliographic Details
Published inRadiotherapy and oncology Vol. 141; pp. 149 - 155
Main Authors Martell, K, Mendez, L.C, Chung, H.T, Tseng, C.L, Alayed, Y, Cheung, P, Liu, S, Vesprini, D, Chu, W, Wronski, M, Szumacher, E, Ravi, A, Loblaw, A, Morton, G
Format Journal Article
LanguageEnglish
Published Ireland Elsevier B.V 01.12.2019
Subjects
Aged
Androgen Antagonists - therapeutic use
Brachytherapy
Brachytherapy - methods
HDR
Hematology, Oncology, and Palliative Medicine
Humans
Intermediate-risk
Male
Middle Aged
Outcomes
Prostate
Prostatic Neoplasms - mortality
Prostatic Neoplasms - pathology
Prostatic Neoplasms - radiotherapy
Radiotherapy Dosage
Retrospective Studies
Brachytherapy
Intermediate-risk
Prostate
Outcomes
HDR
Online AccessGet full text

Cover

More Information
Summary:Highlights•5-year FFBF was 92% in patients with intermediate risk prostate cancer treated with 15 Gy HDR boost. •5-year MFS was 96% in patients with intermediate risk prostate cancer treated with 15 Gy HDR boost.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2019.08.017